Direct comparison of the results obtained with cell-impermeable inhibitor 18 (NCEG2) with those of cell-permeable inhibitor 29 (NCEG-RHB) provides the first concrete evidence that intracellular TG2 activity contributes to the cancer-associated phenotype, at least in the cell lines studied herein. This evidence concerns the gene TGM2 and cancer.